A recent meta-analysis of prospective interventional studies have shown that PEGV, in monotherapy or combined with SRLs, improves glucose metabolism by reducing fasting plasma glucose and insulin levels, HbA1c, and insulin resistance, independently of disease control (33). Here, INS is linked to Insulin resistance.